StocksMediumUpdated•Originally published 10 November 2026•Updated 10 November 2026•
1 min read
Autolus Therapeutics Raises 2026 Revenue Outlook as Net Loss Narrows
Key Facts
1Autolus Therapeutics reported a GAAP EPS loss of $0.21, missing analyst estimates by $0.03.
2The company's revenue reached $41.24M, beating expectations by $1.21M.
Autolus Therapeutics raised its full-year 2026 net product revenue outlook for AUCATZYL to reach or exceed $150 million. The company reported that its quarterly net loss narrowed to $55.1 million during the third quarter of 2026, alongside revenue of $41.24 million.
AUTL closed at $1.32 on November 9, 2026, following a reported GAAP EPS loss of $0.21 which missed analyst estimates by $0.03. The upward revision in annual guidance strengthens the firm's financial outlook within the biotechnology sector as it moves through the final quarter of the year.